Literature DB >> 24547894

Does levosimendan act as a Ca2+ sensitizer or PDE3 inhibitor?: Commentary on Orstavik et al., Br J Pharmacol 171: 5169-5181.

Masao Endoh1.   

Abstract

LINKED ARTICLE: This article is a Commentary on Orstavik O, Ata SH, Riise J, Dahl CP, Andersen GO, Levy FO, Skomedal T, Osnes J-B, and Qvigstad E (2014). PDE3-inhibition by levosimendan is sufficient to account for its inotropic effect in failing human heart . Br J Pharmacol 171: 5169-5181. doi: 10.1111/bph.12647.
© 2015 The British Pharmacological Society.

Entities:  

Keywords:  Ca2+ sensitizer; OR-1896; amrinone; cilostamide; levosimendan; omecamtiv mecarbil; phosphodiesterase inhibitor; pimobendan; positive inotropic effect

Year:  2015        PMID： 24547894      PMCID： PMC4562519          DOI： 10.1111/bph.12649

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  13 in total

1.  Regulation of myocardial contractility by a downstream mechanism.

Authors:  M Endoh
Journal:  Circ Res       Date:  1998-07-27       Impact factor: 17.367

2.  Modification of myofibrillar responsiveness to Ca++ as an inotropic mechanism.

Authors:  J R Blinks; M Endoh
Journal:  Circulation       Date:  1986-03       Impact factor: 29.690

3.  Effects of OR-1896, a metabolite of levosimendan, on force of contraction and Ca2+ transients under acidotic condition in aequorin-loaded canine ventricular myocardium.

Authors:  Reiko Takahashi; Masao Endoh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2002-09-17       Impact factor: 3.000

4.  The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.

Authors:  John G F Cleland; John R Teerlink; Roxy Senior; Evgeny M Nifontov; John J V Mc Murray; Chim C Lang; Vitaly A Tsyrlin; Barry H Greenberg; Jamil Mayet; Darrel P Francis; Tamaz Shaburishvili; Mark Monaghan; Mitchell Saltzberg; Ludwig Neyses; Scott M Wasserman; Jacqueline H Lee; Khalil G Saikali; Cyril P Clarke; Jonathan H Goldman; Andrew A Wolff; Fady I Malik
Journal:  Lancet       Date:  2011-08-20       Impact factor: 79.321

5.  Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart.

Authors:  O Orstavik; S H Ata; J Riise; C P Dahl; G Ø Andersen; F O Levy; T Skomedal; J-B Osnes; E Qvigstad
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

6.  Effects of levosimendan on myocardial contractility and Ca2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit.

Authors:  S Sato; M A Talukder; H Sugawara; H Sawada; M Endoh
Journal:  J Mol Cell Cardiol       Date:  1998-06       Impact factor: 5.000

7.  Effects of new inotropic agents on cyclic nucleotide metabolism and calcium transients in canine ventricular muscle.

Authors:  M Endoh; T Yanagisawa; N Taira; J R Blinks
Journal:  Circulation       Date:  1986-03       Impact factor: 29.690

8.  Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan.

Authors:  H Haikala; J Kaivola; E Nissinen; P Wall; J Levijoki; I B Lindén
Journal:  J Mol Cell Cardiol       Date:  1995-09       Impact factor: 5.000

9.  Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation.

Authors:  Cheng-Kun Du; Sachio Morimoto; Kiyomasa Nishii; Reiko Minakami; Mika Ohta; Naoto Tadano; Qun-Wei Lu; Yuan-Yuan Wang; Dong-Yun Zhan; Misato Mochizuki; Satomi Kita; Yoshikazu Miwa; Fumi Takahashi-Yanaga; Takahiro Iwamoto; Iwao Ohtsuki; Toshiyuki Sasaguri
Journal:  Circ Res       Date:  2007-06-07       Impact factor: 17.367

Review 10.  Mechanisms of action of novel cardiotonic agents.

Authors:  Masao Endoh
Journal:  J Cardiovasc Pharmacol       Date:  2002-09       Impact factor: 3.105
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.